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Background: Celastrol, a Chinese herbal medicine, has shown antitumor activity against 
various tumor cell lines. However, the effect of celastrol on retinoblastoma has not yet been 
analyzed. Additionally, the poor water solubility of celastrol restricts further therapeutic 
  applications. The goal of this study was to evaluate the effect of celastrol nanoparticles (CNPs) 
on r  etinoblastoma and to investigate the potential mechanisms involved.
Methods: Celastrol-loaded poly(ethylene glycol)-block-poly(ε-caprolactone) nanopolymeric 
micelles were developed to improve the hydrophilicity of celastrol. The 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulf-ophenyl)-2H tetrazolium monosodium salt (WST-8) 
assay was used to determine the inhibitory effect of CNPs on SO-Rb 50 cell proliferation 
in vitro. Immunofluorescence was used to evaluate the apoptotic effect of CNPs on nuclear 
morphology, and flow cytometry was used to quantify cellular apoptosis. The expression of 
Bcl-2, Bax, NF-κB p65, and phospo-NF-κB p65 proteins was assessed by Western blotting. 
A human retinoblastoma xenograft model was used to evaluate the inhibitory effects of CNPs 
on retinoblastoma in NOD-SCID mice. Hematoxylin and eosin staining was used to assess the 
apoptotic effects of CNPs on retinoblastoma.
Results: CNPs inhibit the proliferation of SO-Rb 50 cells in a dose- and time-dependent manner 
with an IC50 of 17.733 µg/mL (celastrol-loading content: 7.36%) after exposure to CNPs for 
48 hours. CNPs induce apoptosis in SO-Rb 50 cells in a dose-dependent manner. The expres-
sion of Bcl-2, NF-κB p65, and phospo-NF-κB p65 proteins decreased after exposure to CNPs 
54.4 µg/mL for 48 hours. Additionally, the Bax/Bcl-2 ratio increased, whereas the expression 
of Bax itself was not significantly altered. CNPs inhibit the growth of retinoblastoma and induce 
apoptosis in retinoblastoma cells in mice.
Conclusion: CNPs inhibit the growth of retinoblastoma in mouse xenograft model by inducing 
apoptosis in SO-Rb 50 cells, which may be related to the increased Bax/Bcl-2 ratio and the inhi-
bition of NF-κB. CNPs may represent a potential alternative treatment for retinoblastoma.
Keywords: apoptosis, SO-Rb 50 cells, poly(ethylene glycol)-block-poly(ε-caprolactone), 
nanopolymeric micelles, celastrol nanoparticles
Introduction
Retinoblastoma is the most common childhood primary intraocular malignant tumor, 
with an incidence ranging from 1 in 15,000 to 1 in 18,000 live births.1,2 This repre-
sents approximately 4% of all pediatric malignancies, and approximately 5000 new 
cases of retinoblastoma are diagnosed around the world each year. Approximately 
50% of children diagnosed with retinoblastoma survive their malignancy worldwide.3 
Enucleation is the standard therapy for patients with advanced intraocular disease 
and is successful in treating intraocular retinoblastoma.4 Although enucleation can 
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cure unilateral disease in approximately 95% of patients, 
it may result in vision loss and an unsatisfactory cosmetic 
appearance.5 Currently, drugs that induce apoptosis remain 
the main chemotherapeutic agents in medical oncology,6,7 and 
finding potential therapeutic drugs has been a major goal of 
retinoblastoma investigations.
Traditional Chinese herbal medicines provide a highly 
fertile ground for modern drug development. Trypterygium 
wilfordii Hook F, also known as the Thunder of God Vine, 
belongs to the Celastraceae family and has long been used 
in traditional Chinese medicine for the treatment of rheu-
matoid arthritis.8 Celastrol, a tripterine, is extracted from 
T  rypterygium wilfordii Hook F and shows potential for the 
treatment of autoimmune diseases,9 chronic inflammation,10 
and neurodegenerative diseases.11 Recent studies have 
  demonstrated that celastrol can inhibit tumor cell proliferation 
and induce apoptosis.12,13 Further study showed that celastrol 
was a natural inhibitor of proteasome and NF-κB activity.14 
The proteasome is responsible for degrading misfolded intra-
cellular proteins and important cellular modulators, including 
the pro-apoptotic protein Bax.15 Activation of the NF-κB tran-
scription factor has been connected with multiple aspects of 
oncogenesis, including the regulation of apoptosis, cell cycle 
progression, and cell migration.16 Inhibition of proteasome 
and/or NF-κB activity leads to cell death and is currently 
considered an attractive target for the treatment of cancer.
Although celastrol, as a natural inhibitor of the protea-
some and NF-κB activity, can induce apoptosis in a variety 
of tumor cell lines, including U937 cells, human prostate 
cancer cell lines, HL-60 cells, and human melanoma 
cells,12,14,17,18 the effects of celastrol on retinoblastoma 
are still not clear. Furthermore, the poor water solubility 
of celastrol limits its in vivo application. In a previous 
study, we found that poly(ethylene glycol)-block-poly 
(ε-caprolactone) (PEG-b-PCL) micelles had promising 
potential to improve the hydrophilicity of celastrol and 
extend its release.19 Therefore, in this study, we investigated 
the effects of celastrol-loaded PEG-b-PCL nanopolymeric 
micelles on human retinoblastoma and explored the underly-
ing mechanism of these effects.
Materials and methods
Preparation of celastrol-loaded polymer 
micelles
Chinese herbal celastrol (Figure 1A) was purchased from the 
Shanghai Institute of Materia Medica, Chinese Academy of 
Sciences, Shanghai, China. The preparation of celastrol-loaded 
polymer micelles was performed as previously described.19,20 
Briefly, celastrol-loaded PEG-b-PCL micelles were prepared 
by dissolving PEG-b-PCL (2000:1000, Mw/Mn = 1.18, JCS 
Biopolytech, Toronto, Canada; F  igure 1B) (10 mg) and 
celastrol (2 mg) in chloroform (2 mL), and adding the solu-
tion drop-wise to ddH2O (20 mL) under ultrasonic agitation 
using a Type 60 Sonic Dismembrator (Fisher Scientific, 
Pittsburgh, PA). The organic solvent was then removed by 
vacuum distillation using a rotary evaporator to allow micelle 
formation. The samples were further concentrated and washed 
three times using a Millipore Centrifugal Filter Device (MW 
cutoff: 10,000 Da; Millipore, Billerica, MA) to remove free 
celastrol dissolved in the micelle solution, and then filtered 
with a syringe filter (pore size: 0.22 µm) to eliminate large 
polymer or celastrol aggregates.19
In vitro release of celastrol from polymer 
micelles
The celastrol-release study from polymer micelles in vitro 
was performed as previously described.19,20 Briefly, freeze-
dried micelle samples (12 mg each) were resuspended in 
3 mL of phosphate-buffered solution (pH 7.4) or sodium 
acetate buffered solution (pH 5.0) and then transferred 
into a dialysis bag (MW cutoff: 14,000 Da). The bag 
was placed into the same buffered solution (50 mL). The 
release study was performed at 37°C in a New Brunswick 
  Scientific C24 incubator shaker (New Brunswick Scientific, 
Edison, NJ). At selected time intervals, buffered solution 
outside the dialysis bag was removed for reverse-phase high 
  performance liquid chromatography columns (UltiMate 
3000 HPLC System, Thermo Scientific, Sunnyvale, CA; 
5 µm, 4.6 × 250 mm) analysis and replaced with fresh buffer 
saline. Celastrol concentration was calculated based on the 
absorbance intensity at 425 nm. The cumulative amount of 
drug released was calculated, and the percentages of drug 
released from micelles were plotted against time.
Cell culture
SO-Rb 50 cells, derived from a patient with human retino-
blastoma, have been constantly preserved in our laboratory 
and were cultured in RPMI-1640 medium supplemented 
with 10% fetal bovine serum (Gibco, Gaithersburg, MD), 
100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C 
in a 5% CO2 atmosphere.
In vitro SO-Rb 50 cell proliferation assay
The inhibitory effects of celastrol nanoparticles (CNPs) 
on SO-Rb 50 cell proliferation were measured using the 
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2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulf-ophenyl)-2H tetrazolium monosodium salt (WST-8) 
reagent (Nacalai Tesque, Kyoto, Japan) according to the 
manufacturer’s protocol.21 SO-Rb 50 cells were plated at a 
density of 2 × 103 per well in triplicate in fresh medium for 
24 hours. The CNPs were then diluted to appropriate concen-
trations and immediately applied to the cells. Dose-dependent 
inhibition was assessed by exposing cells to various concen-
trations of CNPs (0–54.4 µg/mL) and the same dosage of 
PEG-b-PCL micelles without celastrol, and culturing cells 
for an additional 48 hours. A time-dependent inhibition was 
performed by exposing cells to CNPs at a concentration of 
27.2 µg/mL and or the same dose of blank micelles for 24, 48, 
and 72 hours. WST solution (10 µL) was added to each well, 
and the cells were incubated for 4 hours at 37°C. Cell viability 
was measured at 450 nm. Variations in cell morphology 
were captured after treatment with CNPs for 48 hours. For 
comparison, the antiproliferation effect of free celastrol on 
SO-Rb 50 cells was also evaluated for celastrol dissolved in 
dimethyl sulfoxide (0.2%, v/v),   concentrations of 0, 0.25, 0.5, 
1, 2, and 4 µg/mL for 48 hours and at a concentration of 2 µg/
mL for 24, 48, and 72 hours. The measurement protocol was 
followed according to the description above.
Nuclear morphology
SO-Rb 50 cells were allowed to grow on coverslips in a 
six-well culture plate (Corning, NY) for 24 hours. Next, the 
cells were treated with 54.4 µg/mL CNPs or blank micelles 
for 24 hours at 37°C. Cells growing on glass c  overslips 
were fixed with 4% paraformaldehyde for 10   minutes at 
room temperature. The fixed cells were washed twice with 
phosphate-buffered saline. Cells were then stained with 
Hoechst 33342 for 10 minutes. Nuclear morphology was 
observed under a fluorescence microscope. Apoptotic cells 
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Figure 1 The chemical structures of (A) celastrol and (B) PEG-b-PCL nanopolymeric micelles. (C) In vitro drug release profiles of celastrol from PEG-b-PCL micelles 
(celastrol content: 7.36%) in phosphate buffer solutions (ph 7.4) and sodium acetate buffered solution (ph 5.0) at 37°C.
Notes: A typical two-phase-release profile contained a rapid release in the first stage followed by a sustained and slow release over a prolonged time up to several weeks in 
both solutions. Furthermore, celastrol release at pH 5.0 was significantly faster than that at pH 7.4. The data are presented as the means ± standard deviation (n = 3).
Abbreviation: PEG-b-PCL, poly(ethylene glycol)-block-poly(ε-caprolactone).
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were identified by changes in nuclear morphology, such as 
chromatin condensation and fragmentation.
Analysis of apoptosis by annexin  
V-FITC/propidium iodide staining
Samples were labeled with annexin V-fluorescein isothiocya-
nate (FITC; BD Biosciences, San Diego, CA) and propidium 
iodide (PI) double staining according to the manufacturer’s 
instructions, and then analyzed by flow cytometry. Briefly, 
after treatment with CNPs, cells were harvested and washed 
twice with ice-cold phosphate-buffered saline. Next, the 
cells were resuspended in 200 µL of binding buffer (10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/NaOH 
pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2) and 10 µL of 
annexin V-FITC for 15 minutes in the dark. Then, 300 µL 
of binding buffer and 5 µL of PI were added to the samples 
for 15 minutes at room temperature in the dark, according 
to the manufacturer’s instructions. Finally, the samples were 
analyzed using flow cytometry.
Western blot analysis
SO-Rb 50 cells were treated with 54.4 µg/mL CNPs or the 
same dose of blank micelles for 48 hours prior to deter-
mining Bcl-2, Bax, NF-κB p65, and phospho-NF-κB p65 
protein expression. The cells were collected, lysed, and 
the total protein concentration was quantified according to 
the manufacturer’s instructions. An equal amount of each 
protein sample was loaded on sodium dodecyl sulfate gels 
and transferred to polyvinylidene difluoride membranes. 
The membranes were blocked with 5% nonfat dry milk 
at room temperature for 2 hours and incubated with anti-
Bcl-2, anti-Bax, anti-NF-κB p65, anti-phospho-NF-κB 
p65, and anti-glyceraldehyde 3-phosphate dehydrogenase 
primary antibodies (Cell Signaling Technology, Danvers, 
MA) overnight at 4°C. Then, the membranes were washed 
and exposed to goat-anti-rabbit-IgG-HRP (Santa Cruz 
Biotechnology, Santa Cruz, CA) for 1 hour at room tem-
perature, followed by imaging with a chemiluminescent 
substrate. The signal was assayed using the ChemiDoc 
XRs+(Bio-RAD, Hercules, CA) with enhanced chemi-
luminescence and analyzed using Image Lab (ECL). 
Glyceraldehyde 3-phosphate dehydrogenase was used as 
the loading control.
Xenograft tumor model
All animals in this study were used according to the Associa-
tion for Research in Vision and Ophthalmology Statement22 
in a protocol approved by the Zhongshan Ophthalmology 
Center in Sun Yat-sen University (Guangzhou, China). 
Retinoblastoma mouse models were performed as previously 
described.23 Briefly, SO-Rb 50 tumor xenografts were estab-
lished by subcutaneous injection of 5 × 107 cells into the right 
flanks of 5- to 6-week-old female NOD-SCID mice. When 
tumors reached a mean tumor volume of 100–200 mm3, as 
determined by the formula: volume = length × width2 × 0.5, 
the animals were randomly divided into two groups (five 
mice per group). The CNP group received intraperitoneal 
injections of CNPs (27.2 mg/kg/2 days); the control group 
was given the same dose of blank micelles by intraperitoneal 
injection. Tumor size was measured using vernier calipers 
every 4 days. In the tumor survival study, mice were eutha-
nized according to our animal protocol, which instructed 
that the mice be euthanized within 1 week of the tumor size 
reaching .1000 mm3.
histological analysis
Tumor tissue was isolated, fixed in 10% formalin, and 
embedded in paraffin. Subsequently, 4-µm-thick sections 
of tumor tissue were cut and stained with hematoxylin and 
eosin solution. Tissue morphology was assessed by light 
microscopy.
Statistical analysis
All experiments were repeated three times. Quantitative 
variables are presented as the mean ± standard deviation 
and analyzed using the SPSS (v16.0; SPSS, Chicago, IL). 
An independent sample t-test was performed to determine 
the significance of differences between the control and CNP-
treated groups. Differences were considered statistically 
significant at P , 0.05.
Results
The data for celastrol-loading content, measurements of 
dynamic light scattering, and transmission electron micros-
copy analysis of CNP diameters have been collected in our 
previous study. Our results showed that the celastrol-loading 
content is 7.36% and the mean diameter of CNPs with spheri-
cal shapes 48 nm.19
In vitro celastrol-release study
The in vitro release behaviors of celastrol-loaded micelles 
in two different buffered solutions (pH 7.4 and 5.0) were 
studied (Figure 1C). In both solutions, a typical release pro-
file featuring two phases was observed. That is, a relatively 
rapid release occurred in the first stage, followed by sustained 
and slow release over a prolonged time up to several weeks. 
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In comparison with the release at pH 7.4, celastrol release 
from micelles at pH 5.0 is much faster.
Inhibition of cell growth
The inhibitory effect of CNPs on SO-Rb 50 cells was 
assessed using the WST-8 assay, and the results are shown 
in Figure 2. SO-Rb 50 cells exposed to CNPs for 48 hours 
at concentrations ranging from 3.4–54.4 µg/mL showed 
decreased cell viability as a function of concentration. Cell 
viability was approximately 30% relative to the control 
cells at a concentration of 27.2 µg/mL CNPs. Changes in 
the morphology of cells revealed that increasing the amount 
of CNPs decreased the number and size of SO-RB 50 cells 
(Figure 2A). Cell viability was determined after treatment 
with either blank micelles or CNPs at different concentra-
tions (Figure 2B). CNPs had a dose-dependent inhibitory 
effect on proliferation with an IC50 value of 17.733 µg/mL 
after exposure to CNPs for 48 hours. The IC50 of free 
celastrol on SO-Rb 50 cells was 0.843 µg/mL. Figure 2C 
demonstrates a time-dependent decrease in the cell   viability 
of SO-Rb 50 cells. CNP-treated cells (27.2 µg/mL) had a 
viability of 31.94% compared to controls following expo-
sure for 48 hours. Free celastrol revealed an enhanced 
inhibitory effect on SO-Rb 50 cells at different time points 
(Figure 2C). Therefore, it can be concluded that the CNPs 
inhibited proliferation of human SO-Rb 50 cell growth in 
both a dose- and time-dependent manner.
Apoptosis
To investigate the effect of CNPs on apoptosis, we stained 
SO-Rb 50 cells with Hoechst 33342 after 24 hours of expo-
sure to 54.4 µg/mL CNPs, and subsequently, examined 
changes in cell morphology using a fluorescence microscope. 
Figure 3 depicts the significant morphological changes in 
nuclear chromatin after treatment with CNPs for 24 hours. 
Untreated cells contain round nuclei with homogeneous 
chromatin (Figure 3A), whereas the nuclei of cells treated 
with CNPs display classic morphological characteristic of 
apoptosis, including a reduction in nuclear size, chromatin 
condensation, and DNA fragmentation (Figure 3B).
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Figure 2 CNPs inhibit the proliferation of human SO-Rb 50 cells in vitro. (A) Morphological variations of SO-Rb 50 cells treated with 0–54.4 µg/mL CNPs for 48 hours 
(100 × magnification). Increasing the amount of CNPs decreased the number and size of SO-RB 50 cells. (B) The dose-dependent effect of CNPs on cell viability. SO-Rb 
50 cells were treated with 0–54.4 µg/mL CNPs for 48 hours. The IC50 is 17.733 µg/mL when exposed to CNPs for 48 hours. (C) The time-dependent effect of CNPs on the 
cell viability. SO-Rb 50 cells were, respectively, treated with 27.2 µg/mL CNPs and 2 µg/mL free celastrol dissolved in 0.2% (v/v) DMSO for 0, 24, 48, and 72 hours.
Notes: The medium (0.2% DMSO) and blank micelles without celastrol showed a cell viability of greater than 95%. The results are reported as the means ± standard deviation (n = 3) 
which were performed in triplicate. Statistical significance was based on the difference compared to control cells treated with medium (*P < 0.01, error bar, 95% CI).
Abbreviations: CI, confidence interval; CNPs, celastrol nanoparticles; Cel, celastrol; DMSO, dimethyl sulfoxide.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2393
Antitumor activity of celastrol nanoparticles in retinoblastoma tumorsInternational Journal of Nanomedicine 2012:7
To quantify cellular apoptosis, the SO-Rb 50 cells were 
treated with CNPs at concentrations of 0, 27.2, 54.4, and 
108.8 µg/mL for 24 hours. The cells were subsequently 
co-stained with annexin V-FITC/PI and analyzed by flow 
cytometry. Representative dot plots of annexin V-FITC/PI 
staining of SO-Rb 50 cells are shown in Figure 4A, and the 
percentage of apoptotic cells relative to CNP concentration 
are shown in Figure 4B. Only a small number of apoptotic 
cells were detected in 0 and 27.2 µg/mL CNP-treated groups. 
However, a significant increase in the number of apoptotic 
cells could be detected in the 54.4 and 108.8 µg/mL CNP-
treated groups. The number of SO-Rb 50 cells undergo-
ing early- and late-stage apoptosis were 6.7% and 24.4%, 
respectively, following incubation with 54.4 µg/mL CNPs 
for 24 hours. The corresponding numbers in the 108.8 µg/mL 
CNP treatment group were 6.3% and 48.4%, respectively. 
This demonstrates that CNPs induced apoptosis, especially 
late-stage apoptosis, in a dose-dependent manner.
Effect on apoptotic proteins
We determined the expression levels of Bcl-2, Bax, NF-κB 
p65, and phospho-NF-κB p65 to understand the effect of 
CNPs on apoptosis-related proteins in SO-Rb 50 cells. 
After 48 hours of exposure to 54.4 µg/mL CNPs, the levels 
of Bcl-2, NF-κB p65, and phospho-NF-κB p65 decreased 
significantly (Figure 5A). Although the expression of Bax 
showed little change, the ratio of Bax/Bcl-2 increased sig-
nificantly (Figure 5B).
Antitumor effect in vivo
Following the investigation of apoptosis induction in SO-Rb 
50 cells in vitro, the antitumor effect of celastrol   nanoparticles 
was evaluated in vivo. We established a retinoblastoma 
xenograft model by injecting SO-Rb 50 cells into NOD/
SCID mice. Administration of 27.2 mg/kg CNPs every 
other day for 16 days substantially suppressed tumor volume 
(Figure 6A) and reduced tumor weight (Figure 6C). The 
average tumor volume in the control mice increased from 
107.08 ± 8.60 mm3 to 1091.41 ± 75.74 mm3 after 16 days, 
whereas the average tumor volume in the CNP-treated mice 
decreased from 112.36 ± 7.52 mm3 to 76.11 ± 6.14 mm3 
(Figure 6A). Additionally, the average tumor weight in 
the control group was 623.20 ± 108.85 mg, whereas the 
average tumor weight in the CNP-treated group was only 
58.80 ± 18.13 mg (Figure 6C), indicating a significant inhibi-
tion of tumor growth. However, the same dose of CNPs had 
no significant effect on the body weight of mice compared 
to the control group (Figure 6B).
histological examination
In control tumor tissue sections, the retinoblastoma cell nuclei 
were large with prominent nucleoli, and only a few cells 
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Figure 4 Annexin V-FITC/PI double staining analysis of apoptosis in SO-Rb 50 cells 
at 24 hours post-treatment. (A) Dot plot for flow cytometric analysis of apoptotic 
cells. Living cells tested negative for both annexin V-FITC and PI. Populations testing 
annexin V positive/PI negative were classified as early-stage apoptotic cells, and 
double-positive cells  were classified as late-stage apoptotic cells.  (B)  Bar graph 
quantifying  the  percentage  of  dead,  living,  early-stage  apoptotic,  and  late-stage 
apoptotic cells according to treatment.
Note: The values shown are the mean of three independent experiments.
Abbreviations:  FITC,  fluorescein  isothiocyanate;  PI,  propidium  iodide;  CNPs, 
celastrol nanoparticles.
Figure 3 CNPs induce apoptosis in SO-Rb 50 cells. Fluorescence micrographs of 
SO-Rb 50 cells are shown after exposure to (A) blank micelles and (B) CNPs at 
54.4 µg/mL for 24 hours (400× magnification).
Notes: Cells were stained with hoechst 33342 to visualize nuclear morphology. 
Blank  micelle-treated  SO-Rb  50  cells  have  round  nuclei  with  homogeneous 
chromatin.  The  cells  treated  with  CNPs  are  characterized  by  chromatin 
condensation, a reduction of nuclear size, and nuclear fragmentation (red arrows 
show nuclear fragmentation).
Abbreviation: CNPs, celastrol nanoparticles.
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showed a reduction in nuclear size with deeply stained nuclei 
and condensed cytoplasm (Figure 7A). In contrast, a greater 
number of cells had hyperchromatic nuclei and a reduction 
in nuclear size in the CNP-treated group (Figure 7B).
Discussion
In this study, we demonstrate that CNPs can suppress the 
growth of human retinoblastoma in a xenograft mouse model. 
One of the major mechanisms through which CNPs mediate 
their effects against retinoblastoma is by inducing apoptosis 
in tumor cells.
Celastrol can inhibit the proliferation of multiple 
tumor cell lines in vivo and in vitro through the induction 
of apoptosis in tumor cells and the suppression of tumor 
angiogenesis.13,14,24 However, the effect of celastrol on retino-
blastoma has not previously been addressed. Additionally, 
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growth as measured by tumor volume. (B) As demonstrated by the change in body weight, CNPs had little toxicity in mice at the doses tested. (C) Solid tumors in mice 
treated with CNPs were significantly smaller than those in control mice.
Notes: *P , 0.001 versus control. Error bars: 95% CI.
Abbreviation: CNPs, celastrol nanoparticles.
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the poor water solubility of celastrol is an obstacle to further 
therapeutic applications. PEG-b-PCL polymeric micelles 
have been widely investigated in medical research due to 
their ability to increase hydrophilicity and extend the release 
of a drug.25–27 Drug-loaded polymeric micelles target tumor 
tissues through enhanced permeation and retention of the 
vasculature surrounding tumors.28 Therefore, nanopolymeric 
micelles have been considered as an important and attractive 
class of drug carriers. Previously, it has been reported that 
PEG-b-PCL micelles loaded with anticancer drugs could 
significantly improve the efficacy of chemotherapeutic 
agents.29 Therefore, we chose PEG-b-PCL as the celastrol 
delivery carrier to further study the effects of CNPs on 
retinoblastoma in a xenograft mouse model. In a previous 
study, we demonstrated that PEG-b-PCL could significantly 
improve the water solubility of celastrol.19 We found a typical 
two-phase-release profile of celastrol release from micelles. 
Additionally, faster release of celastrol in acidic conditions 
was also observed, consistent with previous reports.27 This 
pH-dependent releasing behavior is of particular interest 
in achieving the tumor-targeted celastrol delivery with 
micelles.30 Micellar particles are generally internalized inside 
the cells by endocytosis; therefore, faster release inside the 
lysosome of tumor cells (at approximately pH 5.0) may occur 
due to the decreased pH values.31
Celastrol is a component of several herbal medicines that 
have been known to have antitumor activity. Celastrol itself 
has antiproliferative activity on different tumor cell lines.32 
In the present study, an in vitro WST assay demonstrated 
that CNPs inhibit the proliferation of SO-Rb 50 cells in a 
dose-dependent and time-dependent manner, with an IC50 
value of 17.733 µg/mL (celastrol-loading content: 7.36%, 
concentration of celastrol: 1.305 μg/mL). Free celastrol had 
an IC50 value of 0.843 µg/mL and also showed an enhanced 
inhibitory effect on SO-Rb 50 cells at different time points. 
The lower potency of micelle-delivered celastrol may be due 
to a delayed celastrol release from micelles, which is consis-
tent with our study of in vitro celastrol release study.
To further analyze CNP-induced cytotoxicity, we 
investigated the apoptotic effects of CNPs on SO-Rb 
50 cells. Apoptosis is an important method of maintaining 
the balance between cell division and cell death,33 and the 
induction of apoptosis in tumor cells is an important focus 
of antitumor drug discovery.34 This study demonstrates 
that morphological changes occur in the nucleus of SO-Rb 
50 cells following treatment with CNPs for 24 hours. Flow 
analysis revealed a dose-dependent increase in apoptosis in 
CNP-treated SO-Rb 50 cells. In vivo, CNPs significantly 
inhibited the growth of retinoblastoma in a xenograft tumor 
model in NOD-SCID mice. Additionally, hematoxylin and 
eosin staining showed that CNPs induced apoptosis in the 
retinoblastoma cells.
Bcl-2 family members include both anti-apoptotic 
  proteins, such as Bcl-2, and pro-apoptotic proteins, such as 
Bax.35 These proteins are essential in regulating the mitochon-
drial apoptotic pathway.36 Overexpression of Bax enhances 
cell apoptosis, whereas Bcl-2 inhibits this process.37 A change 
in the Bax/Bcl-2 ratio could lead to cell death.38 In the cur-
rent study, CNPs downregulated the expression of Bcl-2, and 
thereby increased the Bax/Bcl-2 ratio in SO-Rb 50 cells. This 
suggests that CNPs could change the expression of apoptotic 
proteins and may trigger apoptosis through a mitochondria-
dependent pathway in SO-Rb 50 cells.
NF-κB is a transcription factor that is strongly related 
to the inhibition of apoptosis, in addition to contribut-
ing to tumor growth, metastasis, and chemoresistance.35 
Overexpression of NF-κB factors has been shown to block 
  apoptosis.39 In human retinoblastoma cells, the transcriptional 
activity of NF-κB is necessary for survival.40 A recent study 
suggested that the expression of p65 and c-Rel proteins, 
NF-κB transcription factor family members, represented 
a reliable marker for human retinoblastoma.41 Celastrol 
has previously been considered a natural NF-κB inhibi-
tor.13 In this study, SO-Rb 50 cells expressed higher levels 
of NF-κB p65 and phospho-NF-κB p65, consistent with 
previous studies.40 In contrast, the expression of NF-kB p65 
and phospho-NF-κB p65 was decreased in the CNP-treated 
group. Celastrol displayed potent suppression of NF-κB p65 
activity in human retinoblastoma cells. This may be one of 
the mechanisms through which CNPs induce apoptosis in 
SO-Rb 50 cells.
Figure 7 CNPs induce apoptosis in retinoblastoma cells. Retinoblastoma induced 
by inoculation with SO-Rb 50 cells were treated with blank micelles and CNPs 
at  27.2  mg/kg  every  other  day  for  3  weeks.  Retinoblastoma  tissue  sections  of 
(A) control and (B) CNP groups were stained with hematoxylin and eosin.
Note:  A  greater  number  of  cells  showed  a  reduction  in  nuclear  size,  deeply 
stained  nuclei,  and  condensed  cytoplasm  in  the  CNP  group  (red  arrows  show 
hyperchromatic nuclei).
Abbreviation: CNPs, celastrol nanoparticles.
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Conclusion
In this study, we demonstrate that CNPs significantly inhibit 
the proliferation of human retinoblastoma SO-Rb 50 cells 
in a dose- and time-dependent manner. CNPs inhibit retino-
blastoma growth in a xenograft mouse model by inducing 
apoptosis in SO-Rb 50 cells, which may be related to an 
increase in the Bax/Bcl-2 ratio and inhibition of NF-κB. 
CNPs may represent a potential alternative treatment for 
retinoblastoma.
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